AXSM Axsome Therapeutics Inc
11,084
$76.94
$1.00
(1.32%)
| Watchers | 11,084 |
| 52-Wk Low | $55.02 |
| 52-Wk High | $98.40 |
| Market Cap | $3.65B |
| Volume | 1.28M |
| 52-Wk High | $98.40 |
| 52-Wk Low | $55.02 |
Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of DirectorsPR Newswire • 8 days ago
Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors Ginkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of Directors PR Newswire...
Share to Feed
Latest Ratings for AXSM
DateFirmActionFromTo Mar 2022SVB LeerinkMaintainsOutperform Nov 2021SVB LeerinkMaintainsOutperform Aug 2021HC Wainwright & Co.MaintainsBuy
View More Analyst Ratings for...
Latest Ratings for AXSM
DateFirmActionFromTo Mar 2022SVB LeerinkMaintainsOutperform Nov 2021SVB LeerinkMaintainsOutperform Aug 2021HC Wainwright & Co.MaintainsBuy
View More Analyst Ratings for...
NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Axsome Therapeutics, Inc...
Related Stocks: AXSM...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) had its target price increased by investment analysts at Mizuho from $108.00 to $109.00 in a research note issued on Thursday, Benzinga reports...
Axsome Therapeutics (NASDAQ:AXSM - Free Report) had its price objective increased by Citigroup from $125.00 to $127.00 in a research report released on Tuesday, Benzinga reports. The brokerage...
Axsome Therapeutics (NASDAQ:AXSM - Free Report) had its price target increased by Royal Bank of Canada from $123.00 to $128.00 in a research report sent to investors on Tuesday, Benzinga reports...